ARTEMISMED Share Price Target 2050
CAGR-based price projection for Artemis Medicare Services Limited (ARTEMISMED) targeting 2050, derived from official NSE exchange closing prices.
Current Market Snapshot
Year-by-Year Price Projection
| Year | Bear Case | Base Case | Bull Case |
|---|---|---|---|
| 2027 | Rs 399 | Rs 493 | Rs 839 |
| 2028 | Rs 474 | Rs 723 | Rs 2,094 |
| 2029 | Rs 562 | Rs 1,060 | Rs 5,224 |
| 2030 | Rs 667 | Rs 1,555 | Rs 13,032 |
| 2031 | Rs 791 | Rs 2,280 | Rs 32,513 |
| 2032 | Rs 939 | Rs 3,343 | Rs 81,115 |
| 2033 | Rs 1,114 | Rs 4,901 | Rs 202,367 |
| 2034 | Rs 1,321 | Rs 7,186 | Rs 504,870 |
| 2035 | Rs 1,568 | Rs 10,537 | Rs 1,259,563 |
| 2036 | Rs 1,860 | Rs 15,449 | Rs 3,142,391 |
| 2037 | Rs 2,207 | Rs 22,653 | Rs 7,839,721 |
| 2038 | Rs 2,619 | Rs 33,214 | Rs 19,558,747 |
| 2039 | Rs 3,107 | Rs 48,700 | Rs 48,795,688 |
| 2040 | Rs 3,686 | Rs 71,406 | Rs 121,736,796 |
| 2041 | Rs 4,374 | Rs 104,699 | Rs 303,712,234 |
| 2042 | Rs 5,189 | Rs 153,514 | Rs 757,709,455 |
| 2043 | Rs 6,157 | Rs 225,089 | Rs 1,890,353,939 |
| 2044 | Rs 7,306 | Rs 330,035 | Rs 4,716,105,878 |
| 2045 | Rs 8,668 | Rs 483,911 | Rs 11,765,867,857 |
| 2046 | Rs 10,285 | Rs 709,531 | Rs 29,353,803,758 |
| 2047 | Rs 12,203 | Rs 1,040,345 | Rs 73,232,659,548 |
| 2048 | Rs 14,478 | Rs 1,525,398 | Rs 182,702,809,783 |
| 2049 | Rs 17,179 | Rs 2,236,603 | Rs 455,811,886,510 |
| 2050 | Rs 20,382 | Rs 3,279,403 | Rs 1,137,171,760,689 |
Frequently Asked Questions
What is the ARTEMISMED share price target for 2050?
Based on historical growth analysis, the ARTEMISMED share price target for 2050 ranges from Rs 20,382 (conservative) to Rs 3,279,403 (base case) to Rs 1,137,171,760,689 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.
What is the current share price of ARTEMISMED?
The current market price of ARTEMISMED (Artemis Medicare Services Limited) is Rs 336.40. The 52-week high is Rs 366.60 and 52-week low is Rs 228.20.
Is ARTEMISMED a good stock to buy for the long term?
Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.
What methodology does BrokerLens use for ARTEMISMED price targets?
BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 18.6% CAGR), Base (46.6% CAGR), and Bull (optimistic at 149.5% CAGR). These are statistical projections, not guaranteed forecasts.